What Analysts Really Pressed LLY On This Quarter

Eli Lilly’s growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.

After around 85% run over the past year, Eli Lilly (LLY) just posted a quarter with 48% revenue growth, numbers that can make a stock feel invincible. But for a company trading at this valuation, the only question that matters is what comes next. On its latest call, analysts repeatedly circled one central worry: with growth this strong, are the first cracks starting to show in the forward-looking story? The sharpest questions were not about the quarter that just closed, but about the new products and guidance that have to carry the momentum from here.

The New Pill’s Slow Start

The first challenge centered on Foundayo, the company’s new oral obesity drug and a critical piece of its future. If the injectable drugs built the franchise, the pill is supposed to broaden it to millions more. The problem, as one analyst framed it, is that the U.S. launch curve has looked “somewhat slower than anticipated.” This is a direct challenge to execution on a product investors are counting on to be the next large growth engine. The stakes are simple: a blockbuster launch keeps the story going, while a stumble gives competitors an opening and spooks investors in a high-multiple stock.

Management’s response was to argue the inflection point is happening right now. The company reported that in the last week of July, it saw a significant uptick, “almost doubling the volume that we had just a month ago.” They added that new patient starts on Foundayo are now approaching one out of every four. It counters the “slow start” narrative by pointing to very recent momentum, but it also implicitly concedes the early weeks were softer. The answer was confident, but the proof will be in the coming months.

A Guide That Taps The Brakes

The second point of pressure came on guidance. Lilly raised its full-year revenue forecast to a range of $85 billion to $87 billion, up from its prior estimate of $82.5 billion to $84.5 billion. But the math behind that raise seemed to imply a revenue deceleration in the second half of the year compared to the rapid pace of Q2. For a growth story this strong, any hint of a slowdown gets scrutinized. It forces the question of whether the current trajectory is truly sustainable.

The CFO’s answer was direct and technical. He explained the apparent slowdown was an illusion created by a few factors: one-off items and prior-period rebate adjustments that artificially boosted first-half results, which won’t repeat. More importantly, he noted the second half of 2025 was unusually strong due to the “bolus” of Mounjaro launches in international markets, making for a tougher year-over-year comparison. This was a credible, numbers-driven explanation that defused the concern by reframing it as an issue of accounting and timing, not a fundamental weakening of the business.

What To Watch Now

Management met the key challenges head-on, arguing that the growth story is fully intact. They answered the guidance question convincingly and provided specific, near-term data to counter worries about the Foundayo launch. But what remains an open question is whether the recent Foundayo inflection is a durable trend or just a short-term blip from new marketing and access programs. The one thing to watch next quarter is that prescription data. It will be the clearest signal of whether Lilly’s next growth engine has truly gained traction. For investors who want to look at a basket of similar names, a healthcare ETF like XLV offers broader exposure to the sector.

Where One Stock’s Open Questions Fit A Bigger Plan

Every stock carries unresolved questions like these, and no earnings call settles all of them. Owning a sector fund spreads that risk across more names, but it is still one bet on one theme: when the theme wobbles, the whole basket wobbles with it.

The Trefis High Quality (HQ) Portfolio takes the next step out. It holds about 30 businesses diversified across sectors, selected not on a theme but on quality itself: consistent cash generation, strong margins, and resilient balance sheets. No single unresolved debate, and no single industry, carries your result. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Track the debates on names you like, on top of a core built on quality rather than any one story.